- United States
- /
- Medical Equipment
- /
- NasdaqGS:ATEC
Market Participants Recognise Alphatec Holdings, Inc.'s (NASDAQ:ATEC) Revenues
Alphatec Holdings, Inc.'s (NASDAQ:ATEC) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment opportunity when you consider close to half the companies in the Medical Equipment industry in the United States have P/S ratios below 3.1x. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/S.
View our latest analysis for Alphatec Holdings
What Does Alphatec Holdings' Recent Performance Look Like?
Recent times have been advantageous for Alphatec Holdings as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Alphatec Holdings.Do Revenue Forecasts Match The High P/S Ratio?
In order to justify its P/S ratio, Alphatec Holdings would need to produce impressive growth in excess of the industry.
If we review the last year of revenue growth, the company posted a terrific increase of 41%. Pleasingly, revenue has also lifted 238% in aggregate from three years ago, thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing revenue over that time.
Turning to the outlook, the next three years should generate growth of 18% per year as estimated by the ten analysts watching the company. That's shaping up to be materially higher than the 9.7% each year growth forecast for the broader industry.
In light of this, it's understandable that Alphatec Holdings' P/S sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.
What We Can Learn From Alphatec Holdings' P/S?
Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
As we suspected, our examination of Alphatec Holdings' analyst forecasts revealed that its superior revenue outlook is contributing to its high P/S. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. It's hard to see the share price falling strongly in the near future under these circumstances.
Before you settle on your opinion, we've discovered 4 warning signs for Alphatec Holdings (1 is concerning!) that you should be aware of.
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ATEC
Alphatec Holdings
A medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally.
Undervalued with reasonable growth potential.